Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has shared an update.
IRLAB Therapeutics AB announced a new patent for Mesdopetam, enhancing its US patent protection and extending it into the 2040s. The company also reported positive Phase I results for IRL757, supporting its ongoing development. Despite a decrease in net sales and operating profit, a rights issue raised SEK 115.7 million, bolstering the company’s financial position.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a pharmaceutical company focused on developing novel treatments for neurological disorders. The company specializes in creating drug candidates and has a strong project portfolio aimed at addressing Parkinson’s disease and other central nervous system disorders.
Average Trading Volume: 129,322
Technical Sentiment Signal: Sell
Current Market Cap: SEK260.9M
Learn more about IRLAB.A stock on TipRanks’ Stock Analysis page.